atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.
Company profile
Ticker
AVIR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Atea Pharmaceuticals Securities Corporation ...
IRS number
460574869
AVIR stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Feb 24
8-K
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
21 Jun 23
DEFA14A
Additional proxy soliciting materials
12 Jun 23
DEFA14A
Additional proxy soliciting materials
25 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
Transcripts
AVIR
Earnings call transcript
2023 Q4
28 Feb 24
AVIR
Earnings call transcript
2023 Q3
8 Nov 23
AVIR
Earnings call transcript
2023 Q2
8 Aug 23
AVIR
Earnings call transcript
2023 Q1
8 May 23
AVIR
Earnings call transcript
2022 Q4
28 Feb 23
AVIR
Earnings call transcript
2022 Q3
8 Nov 22
AVIR
Earnings call transcript
2022 Q2
9 Aug 22
AVIR
Earnings call transcript
2022 Q1
10 May 22
AVIR
Earnings call transcript
2021 Q4
1 Mar 22
AVIR
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
SC 13G/A
EcoR1 Capital, LLC
15 Feb 24
SC 13G/A
EcoR1 Capital, LLC
15 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Sommadossi Jean-Pierre
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
SC 13G
BML Investment Partners, L.P.
7 Feb 24
4
Andrea Corcoran
2 Feb 24
4
Jean-Pierre Sommadossi
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 137.89 mm | 137.89 mm | 137.89 mm | 137.89 mm | 137.89 mm | 137.89 mm |
Cash burn (monthly) | 25.34 mm | 3.24 mm | 13.60 mm | 13.12 mm | 5.86 mm | 7.09 mm |
Cash used (since last report) | 171.91 mm | 21.95 mm | 92.24 mm | 89.04 mm | 39.78 mm | 48.12 mm |
Cash remaining | -34.02 mm | 115.93 mm | 45.65 mm | 48.84 mm | 98.10 mm | 89.77 mm |
Runway (months of cash) | -1.3 | 35.8 | 3.4 | 3.7 | 16.7 | 12.7 |
Institutional ownership, Q3 2023
86.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 121 |
Opened positions | 8 |
Closed positions | 21 |
Increased positions | 44 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 166.50 bn |
Total shares | 73.13 mm |
Total puts | 26.00 k |
Total calls | 74.90 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.19 mm | $24.57 bn |
EcoR1 Capital | 7.00 mm | $20.99 bn |
FMR | 6.45 mm | $19.36 bn |
Sommadossi Jean-Pierre | 5.93 mm | $0.00 |
BML Capital Management | 4.80 mm | $14.40 bn |
Vanguard | 4.57 mm | $13.72 bn |
BML Investment Partners | 4.18 mm | $13.18 mm |
Tang Capital Management | 3.60 mm | $10.80 bn |
Bain Capital Life Sciences Fund II | 3.18 mm | $100.35 mm |
Tang Capital Partners | 3.03 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Janet MJ Hammond | Common Stock | Sell | Dispose S | No | Yes | 3.843 | 14,029 | 53.91 k | 35,362 |
1 Feb 24 | John Vavricka | Common Stock | Sell | Dispose S | No | Yes | 3.843 | 11,819 | 45.42 k | 21,515 |
1 Feb 24 | Wayne Foster | Common Stock | Sell | Dispose S | No | Yes | 3.8394 | 12,477 | 47.90 k | 20,857 |
1 Feb 24 | Maria Arantxa Horga | Common Stock | Sell | Dispose S | No | Yes | 3.8414 | 15,870 | 60.96 k | 25,664 |
1 Feb 24 | Sommadossi Jean-Pierre | Common Stock | Sell | Dispose S | No | Yes | 3.845 | 56,910 | 218.82 k | 116,557 |
31 Jan 24 | Janet MJ Hammond | Common Stock | Option exercise | Acquire M | No | No | 0 | 46,800 | 0.00 | 49,391 |
31 Jan 24 | Janet MJ Hammond | Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 225,200 | 936.83 k | 225,200 |
31 Jan 24 | Janet MJ Hammond | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 46,800 | 0.00 | 93,600 |
31 Jan 24 | John Vavricka | Common Stock | Option exercise | Acquire M | No | No | 0 | 33,334 | 0.00 | 33,334 |
31 Jan 24 | John Vavricka | Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 132,800 | 552.45 k | 132,800 |